| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_430c89d97f6839f5364904e710af9704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_716e9a2606ffd4ba1a2a3917e4a402fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_51d2b5cfa53b4e783403c0875a35c781 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1825
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0024 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-15 |
| filingDate |
2016-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b860b6594edc1c8f8a6717ad300b4dc9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_937473f87a0efa92d704f0c93fe03ee8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_942cb8c1e0be08d39718041236d4f53f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba5a480d79a4195b7f26c1e19b20582f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c62505cdb6df3465267285ac70208486 |
| publicationDate |
2019-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10238714-B2 |
| titleOfInvention |
Method for forming an immune-tolerant site and method for attracting immunosuppressive cells |
| abstract |
A method for forming an immune-tolerant site, and a method for attracting immunosuppressive cells, comprising contacting an agent comprising SEK-1005 (Ser, 3-hydroxy-N-[2-hydroxy-1-oxo-2-tetrahydro-2-hydroxy-6-methyl-5-(2-methylpropyl)-2H-pyran-2-yl-propyl]-Leu-Pip(hexahydro-3-pyridazinecarbonyl)-N-hydroxy-Ala-N-methyl-Phe-Pip-rho-lactone) and/or fibroblast growth factor (FGF) with a site in the body tissue. |
| priorityDate |
2015-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |